Literature DB >> 26593291

Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.

Souvik Sarkar1, Christopher L Bowlus2.   

Abstract

Primary sclerosing cholangitis (PSC) is a heterogeneous, idiopathic, inflammatory disorder frequently associated with inflammatory bowel diseases. PSC patients may be classified into several subphenotypes. Investigations of pediatric, nonwhite, and female PSC patients have revealed distinguishing features. The natural history of PSC is variable in progression with numerous possible clinical outcomes. PSC patients may suffer bacterial cholangitis, cholangiocarcinoma, or colorectal adenocarcinoma. Treatments focusing on bile acid therapy and immunosuppression have not proven beneficial. Interest in PSC and international collaboration has led to improved understanding of the heterogeneity and the genetic structure and introduced possible effective therapeutics.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune hepatitis; Diagnosis; IgG4-related sclerosing cholangitis; Primary sclerosing cholangitis; Treatment

Mesh:

Substances:

Year:  2015        PMID: 26593291      PMCID: PMC4662051          DOI: 10.1016/j.cld.2015.08.005

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  48 in total

1.  Cutting edge issues in primary sclerosing cholangitis.

Authors:  Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

2.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.

Authors:  Kiran Bambha; W Ray Kim; Jayant Talwalkar; Heidi Torgerson; Joanne T Benson; Terry M Therneau; Edward V Loftus; Barbara P Yawn; E Rolland Dickson; L Joseph Melton
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

Review 3.  MRCP vs. ERCP in the evaluation of biliary pathologies: review of current literature.

Authors:  Koray Hekimoglu; Yucel Ustundag; Abdurrahim Dusak; Zuhal Erdem; Bulent Karademir; Selim Aydemir; Sadi Gundogdu
Journal:  J Dig Dis       Date:  2008-08       Impact factor: 2.325

4.  Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis.

Authors:  C Weber; R Kuhlencordt; R Grotelueschen; U Wedegaertner; T L Ang; G Adam; N Soehendra; U Seitz
Journal:  Endoscopy       Date:  2008-08-12       Impact factor: 10.093

5.  Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study.

Authors:  Maïté Lewin; Valérie Vilgrain; Violaine Ozenne; Maud Lemoine; Dominique Wendum; Valérie Paradis; Marianne Ziol; Lionel Arrivé; Michel Beaugrand; Raoul Poupon; Dominique Valla; Olivier Chazouillères; Christophe Corpechot
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

6.  Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

Authors:  Kirsten Boonstra; Rinse K Weersma; Karel J van Erpecum; Erik A Rauws; B W Marcel Spanier; Alexander C Poen; Karin M van Nieuwkerk; Joost P Drenth; Ben J Witteman; Hans A Tuynman; Anton H Naber; Paul J Kingma; Henk R van Buuren; Bart van Hoek; Frank P Vleggaar; Nan van Geloven; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Hepatology       Date:  2013-10-17       Impact factor: 17.425

7.  Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.

Authors:  Ewa Wunsch; Jocelyn Trottier; Malgorzata Milkiewicz; Joanna Raszeja-Wyszomirska; Gideon M Hirschfield; Olivier Barbier; Piotr Milkiewicz
Journal:  Hepatology       Date:  2014-07-30       Impact factor: 17.425

Review 8.  Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria.

Authors:  Suresh T Chari
Journal:  J Gastroenterol       Date:  2007-05       Impact factor: 7.527

9.  Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Said Al Mamari; Jelena Djordjevic; John S Halliday; Roger W Chapman
Journal:  J Hepatol       Date:  2012-10-22       Impact factor: 25.083

10.  Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis.

Authors:  Sandra Fischer; Palak J Trivedi; Stephen Ward; Paul D Greig; George Therapondos; Gideon M Hirschfield
Journal:  Int J Exp Pathol       Date:  2014-04-18       Impact factor: 1.925

View more
  10 in total

1.  Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single-Center Study.

Authors:  Henry Shiau; Faith D Ihekweazu; Mansi Amin; Tatiana Fofanova; Tamir Miloh; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-10       Impact factor: 2.839

Review 2.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

Review 3.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

4.  Heterogeneity of Outcomes Following Liver Transplantation for Primary Sclerosing Cholangitis: Age Matters.

Authors:  Paul Martin; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2017-11       Impact factor: 3.199

5.  Human β-Defensin 2 in Primary Sclerosing Cholangitis.

Authors:  Cindy Chang; Ana Lleo; Anchasa Kananurak; Fabio Grizzi; Koichi Tsuneyama; Pietro Invernizzi; Charles L Bevins; Christopher L Bowlus
Journal:  Clin Transl Gastroenterol       Date:  2017-03-16       Impact factor: 4.488

Review 6.  Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience.

Authors:  F Rassam; E Roos; K P van Lienden; J E van Hooft; H J Klümpen; G van Tienhoven; R J Bennink; M R Engelbrecht; A Schoorlemmer; U H W Beuers; J Verheij; M G Besselink; O R Busch; T M van Gulik
Journal:  Langenbecks Arch Surg       Date:  2018-01-19       Impact factor: 3.445

7.  Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes.

Authors:  Yuanyuan Zhang; Jonathan P Jackson; Robert L St Claire; Kimberly Freeman; Kenneth R Brouwer; Jeffrey E Edwards
Journal:  Pharmacol Res Perspect       Date:  2017-08

8.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare.

Authors:  Jessica L Petrick; Baiyu Yang; Sean F Altekruse; Alison L Van Dyke; Jill Koshiol; Barry I Graubard; Katherine A McGlynn
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

9.  Clinical Features and Outcomes of Primary Sclerosing Cholangitis in the Highly Admixed Brazilian Population.

Authors:  Mateus Jorge Nardelli; Paulo Lisboa Bittencourt; Guilherme Grossi Lopes Cançado; Luciana Costa Faria; Cristiane Alves Villela-Nogueira; Vivian Rotman; Eliabe Silva de Abreu; Fernanda Maria Farage Osório; Andreia Silva Evangelista; Liliana Sampaio Costa Mendes; Daniel Ferraz de Campos Mazo; Elodie Bonfim Hyppolito; Adrielly de Souza Martins; Liana Codes; Izabelle Venturini Signorelli; Geisa Perez Medina Gomide; Luciana Agoglia; Claudia Alexandra Pontes Ivantes; Valéria Ferreira de Almeida E Borges; Gabriela Perdomo Coral; Rosamar Eulira Fontes Rezende; Maria Lucia Gomes Ferraz; Debora Raquel Benedita Terrabuio; Eduardo Luiz Rachid Cançado; Claudia Alves Couto
Journal:  Can J Gastroenterol Hepatol       Date:  2021-11-10

Review 10.  Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.

Authors:  Ayesha Shah; Graeme A Macdonald; Mark Morrison; Gerald Holtmann
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.